Low dosages: New chemotherapeutic weapons on the battlefield of immune-related disease

Cellular and Molecular Immunology

Volumn 8, Issue 4, 2011, Pages 289-295

  Liu, Jing ^a   Zhao, Jie ^b   Hu, Liang ^a   Cao, Yuchun ^b   Huang, Bo ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

chemotherapeutic drug; immune related disease; low dosage; mechanism; therapeutic weapon

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DIHYDROFOLATE REDUCTASE; FOLINIC ACID; GAMMA INTERFERON; HIGH MOBILITY GROUP B1 PROTEIN; INTERLEUKIN 2; METHOTREXATE; PACLITAXEL; PLATINUM COMPLEX; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; ROFECOXIB; TAXANE DERIVATIVE; VINBLASTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADVANCED CANCER; ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNE DISEASE; BLADDER CANCER; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CANCER RESISTANCE; CANCER SURVIVAL; CD4+ CD25+ T LYMPHOCYTE; CHRONIC LYMPHATIC LEUKEMIA; COMPETITIVE INHIBITION; CONDYLOMA ACUMINATUM; CROHN DISEASE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG DOSE INCREASE; DRUG MEGADOSE; HEAD AND NECK CANCER; HUMAN; IMMUNE EVASION; IMMUNOREGULATION; INFECTION; INFLAMMATORY DISEASE; LIVER INJURY; LIVER ISCHEMIA; LOW DRUG DOSE; LUNG CANCER; LUNG SMALL CELL CANCER; LYMPHOCYTE PROLIFERATION; LYMPHOMA; MULTIPLE CYCLE TREATMENT; MULTIPLE SCLEROSIS; NEOPLASM; NONHUMAN; OSTEOSARCOMA; OVARY CANCER; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PROGRESSION FREE SURVIVAL; PSORIASIS; REGULATORY T LYMPHOCYTE; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; SARCOMA; SKIN LUPUS ERYTHEMATOSUS; SOLID TUMOR; SYSTEMIC LUPUS ERYTHEMATOSUS; TESTIS CANCER; TUMOR MICROENVIRONMENT; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; HUMANS; NEOPLASMS;

EID: 79960042276     PISSN: 16727681     EISSN: None     Source Type: Journal    
DOI: 10.1038/cmi.2011.6     Document Type: Review

References (88)

1. Hirsch J. An anniversary for cancer chemotherapy. JAMA 2006; 296: 1518-1520. (Pubitemid 44465516)
2. Kuhn A, Ochsendorf F, Bonsmann G. Treatment of cutaneous lupus erythematosus. Lupus 2010; 19: 1125-1136.
3. Cao Y, Zhao J, Yang Z, Cai Z, Zhang B, Zhou Y et al. CD41FOXP31 regulatory T cell depletion by low-dose cyclophosphamide prevents recurrence in patients with large condylomata acuminata after laser therapy. Clin Immunol 2010; 136: 21-29.
4. Boehm IB, Boehm GA, Bauer R. Management of cutaneous lupus erythematosus with low-dose methotrexate: indication for modulation of inflammatory mechanisms. Rheumatol Int 1998; 18: 59-62. (Pubitemid 28432835)
5. Castano AP, Mroz P, Wu MX, Hamblin MR. Photodynamic therapy plus low-dose cyclophosphamide generates antitumor immunity in a mouse model. Proc Natl Acad Sci USA 2008; 105: 5495-5500. (Pubitemid 351753891)
6. Stamp L, Roberts R, Kennedy M, Barclay M, ODonnell J, Chapman P. The use of low dose methotrexate in rheumatoid arthritis-are we entering a new era of therapeutic drug monitoring and pharmacogenomics? Biomed Pharmacother 2006; 60: 678-687. (Pubitemid 44821708)
7. Rampton DS. Methotrexate in Crohns disease. Gut 2001; 48: 790-791.
8. Rich SJ, Bello-Quintero CE. Advancements in the treatment of psoriasis: role of biologic agents. J Manag Care Pharm 2004; 10: 318-325.
9. Sadiq SA, Simon EV, Puccio LM. Intrathecal methotrexate treatment in multiple sclerosis. J Neurol 2010; 257: 1806-1811.
10. Rooney PH, Telfer C, McFadyen MC, Melvin WT, Murray GI. The role of cytochrome P450 in cytotoxic bioactivation: future therapeutic directions. Curr Cancer Drug Targets 2004; 4: 257-265. (Pubitemid 38560074)
11. Kay NE, Geyer SM, Call TG, Shanafelt TD, Zent CS, Jelinek DF et al. Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood 2007; 109: 405-411. (Pubitemid 46105933)
12. Makhani N, Gorman MP, Branson HM, Stazzone L, Banwell BL, Chitnis T. Cyclophosphamide therapy in pediatric multiple sclerosis. Neurology 2009; 72: 2076-2082.
13. Young SD, Whissell M, Noble JC, Cano PO, Lopez PG, Germond CJ. Phase II clinical trial results involving treatment with low-dose daily oral cyclophosphamide, weekly vinblastine, and rofecoxib in patients with advanced solid tumors. Clin Cancer Res 2006; 12: 3092-3098. (Pubitemid 43837356)
14. Awwad M, North RJ. Cyclophosphamide-induced immunologically mediated regression of a cyclophosphamide-resistant murine tumor: a consequence of eliminating precursor L3T41 suppressor T-cells. Cancer Res 1989; 49: 1649-1654. (Pubitemid 19108381)
15. Berd D, Mastrangelo MJ. Effect of low dose cyclophosphamide on the immune system of cancer patients: reduction of T-suppressor function without depletion of the CD81 subset. Cancer Res 1987; 47: 3317-3321. (Pubitemid 17082667)
16. Ghiringhelli F, Larmonier N, Schmitt E, Parcellier A, Cathelin D, Garrido C et al. CD41CD251 regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol 2004; 34: 336-344. (Pubitemid 39255944)
17. Lutsiak ME, Semnani RT, de Pascalis R, Kashmiri SV, Schlom J, Sabzevari H. Inhibition of CD41251 T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 2005; 105: 2862-2868. (Pubitemid 40446280)
18. Zhao J, Cao Y, Lei Z, Yang Z, Zhang B, Huang B. Selective depletion of CD41CD251Foxp31 regulatory T cells by low-dose cyclophosphamide is explained by reduced intracellular ATP levels. Cancer Res 2010; 70: 4850-4858.
19. Daenen LG, Shaked Y, Man S, Xu P, Voest EE, Hoffman RM et al. Low-dose metronomic cyclophosphamide combined with vascular disrupting therapy induces potent antitumor activity in preclinical human tumor xenograft models. Mol Cancer Ther 2009; 8: 2872-2881.
20. Wada S, Yoshimura K, Hipkiss EL, Harris TJ, Yen HR, Goldberg MV et al. Cyclophosphamide augments antitumor immunity: studies in an autochthonous prostate cancer model. Cancer Res 2009; 69: 4309-4318.
21. Dupin N. Genital warts. Clin Dermatol 2004; 22: 481-486. (Pubitemid 40017669)
22. Dunne EF, Markowitz LE. Genital human papillomavirus infection. Clin Infect Dis 2006; 43: 624-629. (Pubitemid 44267125)
23. Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F et al. Metronomic cyclophosphamide regimen selectively depletes CD41CD251 regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 2007; 56: 641-648. (Pubitemid 46348738)
24. Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, Erat A et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 2007; 204: 1257-1265. (Pubitemid 46919862)
25. Lazarowski ER, Boucher RC, Harden TK. Mechanisms of release of nucleotides and integration of their action as P2X- and P2Y-receptor activating molecules. Mol Pharmacol 2003; 64: 785-795. (Pubitemid 37153046)
26. Gamcsik MP, Dolan ME, Andersson BS, Murray D. Mechanisms of resistance to the toxicity of cyclophosphamide. Curr Pharm Des 1999; 5: 587-605. (Pubitemid 29484991)
27. Dirven HA, van OB, van Bladeren PJ. Involvement of human glutathione S-transferase isoenzymes in the conjugation of cyclophosphamide metabolites with glutathione. Cancer Res 1994; 54: 6215-6220. (Pubitemid 24378656)
28. Rajagopalan PT, Zhang Z, McCourt L, Dwyer M, Benkovic SJ, Hammes GG. Interaction of dihydrofolate reductase with methotrexate: ensemble and single-molecule kinetics. Proc Natl Acad Sci USA 2002; 99: 13481-13486. (Pubitemid 35215407)
29. Sterba J, Valík D, Bajciová V, Kadlecová V, Gregorová V, Mendelová D. High-dose methotrexate and/or leucovorin rescue for the treatment of children with lymphoblastic malignancies: do we really know why, when and how? Neoplasma 2005; 52: 456-463. (Pubitemid 41809402)
30. Mantadakis E, Cole PD, Kamen BA. High-dose methotrexate in acute lymphoblastic leukemia: where is the evidence for its continued use? Pharmacotherapy 2005; 25: 748-755. (Pubitemid 40604890)
31. Joannon P, Oviedo I, Campbell M, Tordecilla J. High-dose methotrexate therapy of childhood acute lymphoblastic leukemia: lack of relation between serum methotrexate concentration and creatinine clearance. Pediatr Blood Cancer 2004; 43: 17-22. (Pubitemid 38738267)
32. Gokbuget N, Hoelzer D. High-dose methotrexate in the treatment of adult acute lymphoblastic leukemia. Ann Hematol 1996; 72: 194-201.
33. Skärby TV, Anderson H, Heldrup J, Kanerva JA, Seidel H, Schmiegelow K et al. High leucovorin doses during high-dose methotrexate treatment may reduce the cure rate in childhood acute lymphoblastic leukemia. Leukemia 2006; 20: 1955-1962.
34. Bocci G, Tuccori M, Emmenegger U, Liguori V, Falcone A, Kerbel RS et al. Cyclophosphamide-methotrexate "metronomic" chemotherapy for the palliative treatment of metastatic breast cancer. A comparative pharmacoeconomic evaluation. Ann Oncol 2005; 16: 1243-1252. (Pubitemid 41166506)
35. Gonzalez Baron M, Garcia Giron C, Zamora P, Garcia de Paredes ML, Feliu J, Ordoñez A et al. Non-small-cell lung cancer (NSCLC): chemotherapy in advanced disease. Our experience in ten years. Am J Clin Oncol 1992; 15: 23-28.
36. Giaccone G. Teniposide alone and in combination chemotherapy in small cell lung cancer. Semin Oncol 1992; 19: 75-80.
37. Specenier PM, Vermorken JB. Current concepts for the management of head and neck cancer: chemotherapy. Oral Oncol 2009; 45: 409-415.
38. Algazi AP, Kadoch C, Rubenstein JL. Biology and treatment of primary central nervous system lymphoma. Neurotherapeutics 2009; 6: 587-597.
39. Jaffe N. Osteosarcoma: review of the past, impact on the future. The American experience. Cancer Treat Res 2009; 152: 239-262.
40. Korn S, DeHoratius RJ. Methotrexate in the treatment of rheumatoid arthritis.AmFam Physician 1989; 40: 243-246. (Pubitemid 19260725)
41. Swierkot J, Szechinski J. Methotrexate in rheumatoid arthritis. Pharmacol Rep 2006; 58: 473-492. (Pubitemid 44383273)
42. Sato EI. Methotrexate therapy in systemic lupus erythematosus. Lupus 2001; 10: 162-164.
43. Kalb RE, Strober B, Weinstein G, Lebwohl M. Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference. J Am Acad Dermatol 2009; 60: 824-837.
44. Sun JH, Das KM. Low-dose oral methotrexate for maintaining Crohns disease remission: where we stand. J Clin Gastroenterol 2005; 39: 751-756. (Pubitemid 41361891)
45. Cronstein BN. Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmacol Rev 2005; 57: 163-172. (Pubitemid 41043882)
46. Khanna D, Park GS, Paulus HE, Simpson KM, Elashoff D, Cohen SB et al. Reduction of the efficacy of methotrexate by the use of folic acid: post hoc analysis from two randomized controlled studies. Arthritis Rheum 2005; 52: 3030-3038. (Pubitemid 41447082)
47. Dervieux T, Furst D, Lein DO, Capps R, Smith K, Caldwell J et al. Pharmacogenetic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate: results of a multicentred cross sectional observational study. Ann Rheum Dis 2005; 64: 1180-1185. (Pubitemid 41113353)
48. Genestier L, Paillot R, Fournel S, Ferraro C, Miossec P, Revillard JP. Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells. J Clin Invest 1998; 102: 322-328. (Pubitemid 28335191)
49. Olsen NJ, Murray LM. Antiproliferative effects of methotrexate on peripheral blood mononuclear cells. Arthritis Rheum 1989; 32: 378-385. (Pubitemid 19118662)
50. Chan ES, Cronstein BN. Methotrexate-how does it really work? Nat Rev Rheumatol 2010; 6: 175-178.
51. Alam MS, Kurtz CC, Wilson JM, Burnette BR, Wiznerowicz EB, Ross WG et al. A2A adenosine receptor (AR) activation inhibits pro-inflammatory cytokine production by human CD41 helper T cells and regulates Helicobacter-induced gastritis and bacterial persistence. Mucosal Immunol 2009; 2: 232-242.
52. Allegra CJ, Drake JC, Jolivet J, Chabner BA. Inhibition of phosphoribosylaminoimidazolecarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates. Proc Natl Acad Sci USA 1985; 82: 4881-4885. (Pubitemid 15249910)
53. Thiel M, Chambers JD, Chouker A, Fischer S, Zourelidis C, Bardenheuer HJ et al. Effect of adenosine on the expression of beta2 integrins and L-selectin of human polymorphonuclear leukocytes in vitro. J Leukoc Biol 1996; 59: 671-682. (Pubitemid 26198079)
54. Neurath MF, Hildner K, Becker C, Schlaak JF, Barbulescu K, Germann T et al. Methotrexate specifically modulates cytokine production by T cells and macrophages in murine collagen-induced arthritis (CIA): a mechanism for methotrexate-mediated immunosuppression. Clin Exp Immunol 1999; 115: 42-55. (Pubitemid 29030362)
55. Dolhain RJ, Tak PP, Dijkmans BA, de Kuiper P, Breedveld FC, Miltenburg AM. Methotrexate reduces inflammatory cell numbers, expression of monokines and of adhesion molecules in synovial tissue of patients with rheumatoid arthritis. Br J Rheumatol 1998; 37: 502-508.
56. Sperling RI, Coblyn JS, Larkin JK, Benincaso AI, Austen KF, Weinblatt ME. Inhibition of leukotriene B4 synthesis in neutrophils from patients with rheumatoid arthritis by a single oral dose of methotrexate. Arthritis Rheum 1990; 33: 1149-1155. (Pubitemid 20273302)
57. Thomas R, Carroll GJ. Reduction of leukocyte and interleukin-1 beta concentrations in the synovial fluid of rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum 1993; 36: 1244-1252. (Pubitemid 23303115)
58. Ferrari S, Palmerini E. Adjuvant and neoadjuvant combination chemotherapy for osteogenic sarcoma. Curr Opin Oncol 2007; 19: 341-346. (Pubitemid 46883523)
59. Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 2007; 33: 9-23. (Pubitemid 46137553)
60. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 2007; 7: 573-584. (Pubitemid 47106628)
61. Jamieson ER, Lippard SJ. Structure, recognition, and processing of cisplatin-DNA adducts. Chem Rev 1999; 99: 2467-2498.
62. Sarosy GA, Hussain MM, Seiden MV, Fuller AF, Nikrui N, Goodman A et al. Ten-year follow-up of a phase 2 study of dose-intense paclitaxel with cisplatin and cyclophosphamide as initial therapy for poor-prognosis, advanced-stage epithelial ovarian cancer. Cancer 2010; 116: 1476-1484.
63. Pan P, Cardinal J, Dhupar R, Rosengart MR, Lotze MT, Geller DA et al. Low-dose cisplatin administration in murine cecal ligation and puncture prevents the systemic release of HMGB1 and attenuates lethality. J Leukoc Biol 2009; 86: 625-632.
64. Cardinal J, Pan P, Dhupar R, Ross M, Nakao A, Lotze M et al. Cisplatin prevents high mobility group box 1 release and is protective in a murine model of hepatic ischemia/ reperfusion injury. Hepatology 2009; 50: 565-574.
65. Klune JR, Dhupar R, Cardinal J, Billiar TR, Tsung A. HMGB1: endogenous danger signaling. Mol Med 2008; 14: 476-484.
66. Bianchi ME, Manfredi AA. High-mobility group box 1 (HMGB1) protein at the crossroads between innate and adaptive immunity. Immunol Rev 2007; 220: 35-46. (Pubitemid 350045574)
67. Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002; 418: 191-195. (Pubitemid 34773774)
68. Tsung A, Sahai R, Tanaka H, Nakao A, Fink MP, Lotze MT et al. The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J Exp Med 2005; 201: 1135-1143. (Pubitemid 40524681)
69. Limana F, Germani A, Zacheo A, Kajstura J, Di Carlo A, Borsellino G et al. Exogenous high-mobility group box 1 protein induces myocardial regeneration after infarction via enhanced cardiac C-kit1 cell proliferation and differentiation. Circ Res 2005; 97: e73-e83.
70. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999; 285: 248-251. (Pubitemid 29329996)
71. Ulloa L, Ochani M, Yang H, Tanovic M, Halperin D, Yang R et al. Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation. Proc Natl Acad Sci USA 2002; 99: 12351-12356.
72. Uesugi H, Ozaki S, Sobajima J, Osakada F, Shirakawa H, Yoshida M et al. Prevalence and characterization of novel pANCA, antibodies to the high mobility group nonhistone chromosomal proteins HMG1 and HMG2, in systemic rheumatic diseases. J Rheumatol 1998; 25: 703-709. (Pubitemid 28212378)
73. Wittemann B, Neuer G, Michels H, Truckenbrodt H, Bautz FA. Autoantibodies to nonhistone chromosomal proteins HMG-1 and HMG-2 in sera of patients with juvenile rheumatoid arthritis. Arthritis Rheum 1990; 33: 1378-1383. (Pubitemid 20365569)
74. Ek M, Popovic K, Harris HE, Naucler CS, Wahren-Herlenius M. Increased extracellular levels of the novel proinflammatory cytokine high mobility group box chromosomal protein 1 in minor salivary glands of patients with Sjogrens syndrome. Arthritis Rheum 2006; 54: 2289-2294. (Pubitemid 44051086)
75. Ulfgren AK, Grundtman C, Borg K, Alexanderson H, Andersson U, Harris HE et al. Down-regulation of the aberrant expression of the inflammation mediator high mobility group box chromosomal protein 1 in muscle tissue of patients with polymyositis and dermatomyositis treated with corticosteroids. Arthritis Rheum 2004; 50: 1586-1594. (Pubitemid 38608081)
76. Ayer LM, Senecal JL, Martin L, Dixon GH, Fritzler MJ. Antibodies to high mobility group proteins in systemic sclerosis. J Rheumatol 1994; 21: 2071-2075. (Pubitemid 24352354)
77. Shen FZ, Wang J, Liang J, Mu K, Hou JY, Wang YT. Low-dose metronomic chemotherapy with cisplatin: can it suppress angiogenesis in H22 hepatocarcinoma cells? Int J Exp Pathol 2010; 91: 10-16.
78. Pasquier E, Kavallaris M, Andre N. Metronomic chemotherapy: new rationale for new directions. Nat Rev Clin Oncol 2010; 7: 455-465.
79. Zhu Q, Liu JY, Yang CM, Xu HW, Zhang AZ, Cui Y et al. Influence of antitumor drugs on the expression of Fas system in SW480colon cancer cells. Eur J Gastroenterol Hepatol 2006; 18: 1071-1077. (Pubitemid 44379360)
80. Sundelin K, Roberg K, Grenman R, Hakansson L. Effects of cisplatin, alphainterferon, and 13-cis retinoic acid on the expression of Fas (CD95), intercellular adhesion molecule-1 (ICAM-1), and epidermal growth factor receptor (EGFR) in oral cancer cell lines. J Oral Pathol Med 2007; 36: 177-183.
81. Lacour S, Hammann A, Grazide S, Lagadic-Gossmann D, Athias A, Sergent O et al. Cisplatin-induced CD95 redistribution into membrane lipid rafts of HT29 human colon cancer cells. Cancer Res 2004; 64: 3593-3598. (Pubitemid 38657937)
82. Ménard C, Martin F, Apetoh L, Bouyer F, Ghiringhelli F. Cancer chemotherapy: not only a direct cytotoxic effect, but also an adjuvant for antitumor immunity. Cancer Immunol Immunother 2008; 57: 1579-1587.
83. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008; 454: 436-444.
84. Dougan M, Dranoff G. Immune therapy for cancer. Annu Rev Immunol 2009; 27: 83-117.
85. Rozados VR, Sánchez AM, Gervasoni SI, Berra HH, Matar P, Graciela Scharovsky O. Metronomic therapy with cyclophosphamide induces rat lymphoma and sarcoma regression, and is devoid of toxicity. Ann Oncol 2004; 15: 1543-1550. (Pubitemid 39409746)
86. Borne E, Desmedt E, Duhamel A, Mirabel X, Dziwniel V, Mortier L et al. Oral metronomic cyclophosphamide in elderly with metastatic melanoma. Invest New Drugs 2010; 28: 684-689.
87. Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. Nat Rev Immunol 2008; 8: 59-73.
88. Park S, Jiang Z, Mortenson ED, Deng L, Radkevich-Brown O, Yang X et al. The Therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell 2010; 18: 160-170.